SAN FRANCISCO — Attorneys from Latham & Watkins in Silicon Valley and San Francisco are helping drug maker Allos Therapeutics Inc. merge with AMAG Pharmaceuticals Inc.
The all-stock deal, worth about $686 million in total equity, is designed to bolster AMAG’s commercial portfolio and cut between $55 million and $60 million in costs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
